Loading filters...
Publications per Year (2650 total)
8
1990
6
·
10
·
11
·
15
·
18
1995
22
·
24
·
18
·
31
·
40
2000
34
·
42
·
53
·
63
·
85
2005
70
·
81
·
92
·
82
·
74
2010
77
·
99
·
94
·
114
·
112
2015
98
·
127
·
114
·
118
·
119
2020
149
·
106
·
116
·
119
·
160
2025
49
·
Loaded
Click to load
50 / 2650 papers loaded(scroll for more)
202627 papers
Generaladvanced2026
Post Hoc Subgroup Analysis of Clinical Outcomes in Patients With High-Risk Metastatic Hormone-Naïve Prostate Cancer: Results From a 3-Year Interim Analysis of the J-ROCK Study.
Mizokami A et al. Prostate. 2026
PSMA+advanced2026
[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study.
Sandhu S et al. Lancet Oncol. 2026
Hormone-sensitiveadvanced2026
Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial).
Gupta S et al. Prostate Cancer Prostatic Dis. 2026
PSMA+advanced2026
[177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study.
Privé BM et al. Lancet Oncol. 2026
Generaladvanced2026
Prognostic Impact of Initial Prostate Specific Antigen Half-Life After Abiraterone Acetate in High-Volume Metastatic Hormone-Sensitive Prostate Cancer: Who May Need Triplet Therapy?
Suzuki K et al. Prostate. 2026
Generaladvanced2026
Carboplatin, Cabazitaxel and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase 2 Study.
Antonarakis ES et al. Clin Cancer Res. 2026
Generaladvanced2026
SPOP Mutations in Veterans With Prostate Cancer and Outcomes With Doublet and Triplet Therapy in De Novo Metastatic Hormone Sensitive Prostate Cancer.
Park JJ et al. Prostate. 2026
Generaladvanced2026
Real-World Comparison of Triplet Versus Doublet Therapy in Japanese Patients With High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Propensity-Weighted Analysis From the YUSHIMA Registry and Exploratory Bayesian Evidence Synthesis.
Yasuda Y et al. Prostate. 2026
Hormone-sensitiveadvanced2026
Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study.
Shore ND et al. Prostate Cancer Prostatic Dis. 2026
Hormone-sensitiveadvanced2026
The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With First-Line ARPI Therapy.
Tsutsumi T et al. Prostate. 2026
Hormone-sensitiveadvanced2026
Lipidomic profiling in metastatic prostate cancer captures tumor metabolic rewiring and its modulation by androgen receptor-targeting therapy.
Bleve S et al. Prostate Cancer Prostatic Dis. 2026
Generaladvanced2026
Use of concomitant G-CSF in maintaining efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: A phase III study.
Ong M et al. Eur J Cancer. 2026
Generaladvanced2026
A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer.
Chapin BF et al. Eur Urol. 2026
GeneralAll Stages2026
Inhibition of c-FLIP alongside TRAIL treatment suppresses prostate cancer stem cell activity.
Turnham DJ et al. Br J Cancer. 2026
Hormone-sensitiveadvanced2026
Prostate Cancer Cells With the AR-Low and EMT-High Phenotype Are Vulnerable to NAD+ Synthesis Inhibitors.
Ko HK et al. Prostate. 2026
GeneralAll Stages2026
EXPRESSION OF CONCERN: Functional p53 Determines Docetaxel Sensitivity in Prostate Cancer Cells.
Prostate. 2026
BRCA/HRRadvanced2026
Functional footprints of homologous recombination deficiency in prostate cancer revealed by ctDNA fragmentation and transcription factor accessibility.
Vlachos G et al. Br J Cancer. 2026
Generaladvanced2026
Assessing racial differences in time to subsequent treatment following androgen deprivation therapy among Veterans with prostate cancer.
Friedrich NA et al. Prostate Cancer Prostatic Dis. 2026
Bone metastasesadvanced2026
Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trial.
Dalla Volta A et al. Prostate Cancer Prostatic Dis. 2026
Hormone-sensitiveadvanced2026
Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age.
Shore ND et al. Eur J Cancer. 2026
Hormone-sensitiveadvanced2026
The Impact of Early Modification of Upfront Androgen Receptor Signaling Inhibitors on Survival Outcomes in Metastatic Hormone-Sensitive Prostate Cancer.
Narita S et al. Prostate. 2026
Hormone-sensitiveadvanced2026
Target trial emulation of early docetaxel and enzalutamide for metastatic hormone-sensitive prostate cancer.
Soon YY et al. BJU Int. 2026
Hormone-sensitiveearly2026
Long-Term Follow-Up of Neoadjuvant Enzalutamide Plus Androgen Deprivation Therapy in Localized Prostate Cancer: A Secondary Analysis of a Neoadjuvant Feasibility Trial.
Millan B et al. Prostate. 2026
Hormone-sensitiveadvanced2026
PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: Rationale, Mechanisms, and Clinical Applications.
Oudard S et al. Eur Urol Oncol. 2026
Hormone-sensitiveadvanced2026
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study.
Fizazi K et al. Ann Oncol. 2026
GeneralAll Stages2026
Efficacy of Early Switching From Docetaxel to Cabazitaxel in Castration-Resistant Prostate Cancer.
Kawai T et al. Prostate. 2026
Hormone-sensitiveadvanced2026
Prognostic Effect of KELIM Score of Prostate-Specific Antigen in Hormone-Sensitive Prostate Cancer Patients Treated With Novel Androgen Receptor Inhibitors: Pioneering New Ways.
Ilhan Y et al. Prostate. 2026
202523 papers
Hormone-sensitiveadvanced2025
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial.
Emmett L et al. Lancet Oncol. 2025
Hormone-sensitiveadvanced2025
Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis.
Parekh K et al. Eur Urol Oncol. 2025
Hormone-sensitiveAll Stages2025
PRMT5:MEP50 Are Mediators of Treatment-Induced Neuroendocrine Differentiation in Prostate Cancer.
Nam HS et al. Prostate. 2025
Hormone-sensitiveadvanced2025
A Deep Prostate-specific Antigen Response to Darolutamide plus Androgen Deprivation Therapy Is Associated with Better Clinical Outcomes in the Phase 3 ARANOTE Trial in Patients with Metastatic Hormone-sensitive Prostate Cancer.
Saad F et al. Eur Urol Oncol. 2025
Hormone-sensitiveadvanced2025
Transcriptome profiling of prostatic tumours from ENACT trial patients with or without enzalutamide.
Handa N et al. BJU Int. 2025
Hormone-sensitiveadvanced2025
Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer.
Fizazi K et al. Ann Oncol. 2025
Hormone-sensitiveadvanced2025
Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial.
Grimm MO et al. Eur Urol. 2025
Hormone-sensitiveAll Stages2025
Hormone Therapy Usage Is Associated With Adverse Cardiovascular Events in Prostate Cancer Patients of the All of Us Research Program Cohort.
Yang YJ et al. Prostate. 2025
PSMA+advanced2025
Comparison of two alternative sequences with cabazitaxel and 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: A retrospective multicenter study (LuCaS).
Bolek H et al. Eur J Cancer. 2025
Hormone-sensitiveadvanced2025
Screening for Predictive Factors of Efficacy of Second-Generation Androgen Receptor Axis-Targeted Agents in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer.
Ueda T et al. Prostate. 2025
Hormone-sensitiveadvanced2025
Bipolar androgen therapy for treatment of metastatic castration-resistant prostate cancer: A case series.
Tran EU et al. Prostate. 2025
Hormone-sensitiveadvanced2025
Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial.
Rousseau A et al. Eur J Cancer. 2025
Hormone-sensitiveadvanced2025
Survival outcomes of apalutamide as a starting treatment: impact in real-world patients with metastatic hormone sensitive prostate cancer (OASIS).
Maughan BL et al. Prostate Cancer Prostatic Dis. 2025
Hormone-sensitiveAll Stages2025
Exploiting AR-Synergistic Metabolic Vulnerabilities in Prostate Cancer.
Anzules JM et al. Cancer Res. 2025
Hormone-sensitiveadvanced2025
Efficacy and safety of treatments for metastatic castration-sensitive prostate cancer: A comprehensive network meta-analysis including final ARANOTE data.
Shore N et al. Prostate Cancer Prostatic Dis. 2025
Hormone-sensitiveAll Stages2025
LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer.
Jiang J et al. Cancer Res. 2025
Hormone-sensitiveAll Stages2025
Caloric Restriction Enhances the Efficacy of Antiandrogen Therapy in Prostate Cancer by Inhibiting Androgen Receptor Translation.
Cordova RA et al. Cancer Res. 2025
Bone metastasesAll Stages2025
Clinical features of medication-related osteonecrosis of the jaw in prostate cancer management.
Goto Y et al. BJU Int. 2025
Bone metastasesAll Stages2025
Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study.
Karpinski MJ et al. Eur Urol. 2025
GeneralAll Stages2025
Use of Low-Value Cancer Treatments in Medicare Advantage Versus Traditional Medicare.
Jung J et al. J Clin Oncol. 2025
Hormone-sensitiveearly2025
Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study.
Gong T et al. Prostate Cancer Prostatic Dis. 2025
Hormone-sensitiveadvanced2025
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Smith M et al. Lancet Oncol. 2025
Hormone-sensitiveAll Stages2025
Salvage therapies for biochemical recurrence after definitive local treatment: a systematic review, meta-analysis, and network meta-analysis.
Matsukawa A et al. Prostate Cancer Prostatic Dis. 2025